Pioneering the future of neuroscience derived from nature

Updates & Press Releases

  • Healis Therapeutics announces mission to deliver new class of neuromuscular treatments in psychiatry

    Developing a botulinum toxin-based treatment for major depressive disorder (MDD)

    Read More

Press Highlights

  • Healis Therapeutics Announces Partnership with CKD Bio

    Healis announced it has entered into a supply agreement to develop CKDB-501 for neuropsychiatric indications

    Read More

  • Healis selected to speak on opening day of 2024 Biotech Showcase in San Francisco

    Healis team presenting on company's neurotherapeutics pipeline and clinical development.

    Read More

  • Healis Therapeutics acquires ownership of key botulinum toxin patent

    IP to accelerate the development of botulinum toxin as a candidate for treating major depressive disorder (MDD)

    Read More

CKDB-501A is a BoNT/A neuromodulator in development for neuropsychiatry

Click to read our research

Research Partners